Abstract: Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome is an autosomal dominant disorder in which germline mutations of fumarate hydratase (FH) gene confer an increased risk of cutaneous and uterine leiomyomas and renal cancer. HLRCC-associated renal cancer is highly aggressive and frequently presents as a solitary mass. We reviewed the clinicopathologic features of 9 patients with renal tumors presenting as sporadic cases but who were later proven to have FH germline mutations. Histologically, all tumors showed mixed architectural patterns, with papillary as the dominant pattern in only 3 cases. Besides papillary, tubular, tubulopapillary, solid, and cystic elements, 6 of 9 tumors contained collecting duct carcinoma-like areas with infiltrating tubules, nests, or individual cells surrounded by desmoplastic stroma. Prominent tubulocystic carcinoma-like component and sarcomatoid differentiation were identified. Although all tumors exhibited the proposed hallmark of HLRCC (large eosinophilic nucleolus surrounded by a clear halo), this feature was often not uniformly present throughout the tumor. Prior studies have shown that a high level of fumarate accumulated in HLRCC tumor cells causes aberrant succination of cellular proteins by forming a stable chemical modification, S-(2-succino)-cysteine (2SC), which can be detected by immunohistochemistry. We thus explored the utility of detecting 2SC by immunohistochemistry in the differential diagnosis of HLRCC tumors and other high-grade renal tumors and investigated the correlation between 2SC staining and FH molecular alterations. All confirmed HLRCC tumors demonstrated diffuse and strong nuclear and cytoplasmic 2SC staining, whereas all clear cell (184/184, 100%), most high-grade unclassified (93/97, 96%), and the large majority of "type 2" papillary (35/45, 78%) renal cell carcinoma cases showed no 2SC immunoreactivity. A subset of papillary (22%) and rare unclassified (4%) tumors showed patchy or diffuse cytoplasmic staining without nuclear labeling, unlike the pattern seen with confirmed HLRCC tumors. Sequencing revealed no germline or somatic FH alterations in 14 tumors that either exhibited only cytoplasmic 2SC staining (n = 5) or were negative for 2SC (n = 9), despite their HLRCC-like morphologic features. Our results emphasize the pivotal role of pathologic examination in the diagnosis of HLRCC patients and indicate immunohistochemical detection of 2SC as a useful ancillary tool in the differentiation of HLRCC renal tumors from other high-grade renal cell carcinomas.
H
ereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome is an inherited autosomal dominant disorder in which germline mutations of fumarate hydratase (FH) gene confer an increased risk for cutaneous and uterine leiomyomas and renal cell carcinoma (RCC). [1] [2] [3] [4] In affected families, leiomyomas of the skin or uterus often occur at relatively high frequency, reported to affect 76% of individuals or 100% women at a mean age of 25 or 30 years, respectively. In comparison, the penetrance for RCC is approximately 20% to 30%. 3, 5, 6 However, RCCs associated with HLRCC syndrome are clinically aggressive. Many patients present with local or distant metastasis and succumb to disease within <5 years from initial diagnosis. 3, 7 In addition, unlike other familial RCC syndromes typically developing multiple and bilateral tumors, RCCs in the HLRCC setting can be solitary and unilateral, providing little clue to their hereditary nature.
Histologically, although HLRCC tumors in the early literature were described mostly as type 2 papillary RCC and occasionally as collecting duct carcinoma (CDC), [1] [2] [3] [4] a spectrum of architectural patterns including papillary, tubulopapillary, tubular, solid, and cystic elements has been described. 5, 7 The seminal work by Merino et al 7 proposed the morphologic hallmark of HLRCC renal tumors to be the characteristic nuclear features: a large nucleus with a very prominent inclusion-like eosinophilic nucleolus that is surrounded by a perinucleolar halo. Considering the architectural and nuclear features, the differential diagnosis of HLRCC renal tumors could include a variety of high-grade RCCs of different histologic subtypes, particularly the sporadic papillary RCC with type 2 features, CDC, or high-grade RCC, unclassified. Among the common markers used for the classification of RCC by immunohistochemistry, no specific maker has been identified for HLRCC renal tumors. 7 FH is one of the key enzymes in the Krebs cycle and catalyzes the conversion of fumarate to malate. In HLRCC-associated tumors, a "second-hit" or somatic inactivation of the remaining FH allele causes a functional loss of FH that leads to abnormal intracellular accumulation of fumarate. Interestingly, the increased level of fumarate in cells can spontaneously react with the cysteine sulfhydryl group of proteins to form a stable chemical modification, S-(2-succino)-cysteine (2SC), by a process called protein succination. [8] [9] [10] This modification can be detected by a polyclonal antibody developed against 2SC in cells with increased levels of fumarate, such as adipocytes grown in high-glucose medium as a model of type 2 diabetes. 9 On the basis of this finding, Bardella et al 11 showed that the presence of 2SC positivity by immunohistochemistry predicted genetic alterations of FH gene in patients referred for genetic testing, and this immunoreactivity was absent in a diverse group of non-HLRCC-related tumors. However, this study has not been independently validated.
In this study, we report our experience in HLRCC renal tumors with clinical presentations mimicking sporadic RCCs and describe their expanding clinicopathologic spectrum. We also explore the 2SC immunohistochemical characteristics in HLRCC tumors as well as a variety of high-grade RCCs that enter the differential diagnosis, particularly those with nuclear features imitating HLRCC. We further investigate the correlation between 2SC immunohistochemistry and FH molecular alterations.
MATERIALS AND METHODS

Patients
On the basis of the observations of Merino et al, 7 since 2008 we have been raising the possibility of RCC being associated with the HLRCC syndrome in our pathology reports when a primary or metastatic renal tumor demonstrated the characteristic morphologic features of HLRCC described in that study. 7 Germline genetic testing triggered by this pathologic suspicion allowed us to identify 7 molecularly confirmed cases of HLRCC. We were also able to identify 2 additional cases that presented before 2008 in a retrospective histologic and molecular analysis of RCC, unclassified. All available archival material and gross pathologic reports of these 9 cases were reviewed. Two of the 9 cases were from the consultation files of one of the authors. Clinical data were obtained from a prospectively maintained institutional urology database or from the submitting clinicians (consultation cases). Gross pathology reports and radiology findings provided data regarding tumor laterality, size, and multifocality. Tumor stage was determined using all available clinical and pathologic information and was assigned using the 2010 TNM staging system of the American Joint Committee on Cancer. 12 
2SC Immunohistochemistry
The generation of the 2SC polyclonal antibody and confirmation of its specificity for succinated proteins has previously been described. 9 This antibody is not yet commercially available. Immunohistochemical staining for 2SC was performed using this polyclonal antibody following the method described by Bardella et al. 11 Briefly, antigen retrieval was performed by microwaving in citrate buffer, pH 6.0, for 15 minutes. The tissues were then blocked for endogenous peroxidase, incubated with 2SC polyclonal antibody (1:5000), washed in PBS (0.1% Tween20), followed by incubation with anti-rabbit HRP polymer (Envision; Dako) for 30 minutes. Staining was assessed for intensity (1+ to 3+) and staining pattern (nuclear and cytoplasmic vs. cytoplasmic). Renal tumors from genetically confirmed HLRCC patients were used as positive controls in all experiments.
Besides confirmed HLRCC cases, 2SC immunohistochemistry was performed on multiple tissue microarrays and whole-tissue sections representing 184 clear cell, 45 papillary with type 2 features, and 97 high-grade unclassified RCC tumors, as well as 2 Xp11.2 (TFE3) translocation-associated RCCs and 2 renal medullary carcinomas. Among these cases, except a portion of clear cell RCC, the majority of type 2 papillary and high-grade unclassified RCC cases had at least focally prominent nucleoli that could raise concern for HLRCC tumors. Selected cases of translocationassociated RCC and renal medullary carcinoma with very prominent nucleoli were included. The "type 2" features of papillary RCC were defined as larger tumor cells, with eosinophilic cytoplasm, nuclear pseudostratification, and high nuclear grade. 13, 14 The diagnosis of Xp11 translocation-associated RCC was confirmed by TFE3 immunohistochemistry and fluorescence in situ hybridization (FISH) test. Both renal medullary carcinoma cases showed loss of INI1 by immunohistochemistry.
Molecular Analysis
Frozen or formalin-fixed, paraffin-embedded (FFPE) tissue samples were collected from 16 RCC patients undergoing radical or partial nephrectomy at our institution. All 16 renal tumors exhibited high-grade nuclear features and very prominent nucleoli. All patients had signed informed consent for tissue utilization, and the study was approved by our institutional research board. Tissues were macrodissected to ensure >70% tumor content. DNA was extracted from tumor or matched normal tissue using DNeasy Blood and Tissue Kit or QIAamp DNA FFPE Tissue Kit (Qiagen, Valencia, CA) for frozen or FFPE tissue, respectively, according to the manufacturer's instructions.
FH gene status was examined using the IMPACT assay (Integrated Mutation Profiling of Actionable Cancer Targets). 15, 16 This assay uses solution-phase hybridizationbased exon capture and massively parallel DNA sequencing to capture all protein-coding exons and selected introns of 230 oncogenes, tumor-suppressor genes, and members of pathways deemed actionable by targeted therapies as previously described. Briefly, 93 to 500 ng genomic DNA was used to construct barcoded sequence libraries (New England Biolabs, Kapa Biosystems, NEXTflex), pooled at 100 ng/library, and subjected to exon capture by hybridization (Nimblegen SeqCap). Captured pools were subsequently sequenced on an Illumina HiSeq 2000 to generate paired-end 75 bp reads. Sequence data were analyzed to identify 3 classes of somatic alterations: singlenucleotide variants (MuTect 17 ), small insertions/deletions (indels, GATK 18 ), and copy number alterations. Copy number was computed using tumor:normal ratios of normalized coverage data to determine amplifications and deletions. 16 All candidate FH somatic alterations and FH locus in paired normal controls were reviewed manually using the Integrative Genomics Viewer. 19 
RESULTS
Clinical Presentation of HLRCC Renal Tumors Encountered in a Sporadic Setting
Overall, we identified a group of 9 HLRCC patients with renal tumors who were subsequently confirmed to harbor FH germline mutations either by genetic testing or molecular analysis of their tumors. The clinical characteristics of these cases are summarized in Table 1 . Briefly, there were 5 men and 4 women with a mean age of 36 years (range, 24 to 61 y). No skin leiomyomas were revealed in past history or documented by physical examination at the initial presentation. One patient had previously resected uterine fibroids at age 32, 5 years before presentation with her renal tumor. 20 Imaging studies of another 32-year-old patient showed uterine fibroids at the time of presentation. Two patients had a family history of RCC in first-degree relatives. Other types of cancer (ovarian, breast, and lung) in parents were reported in 3 cases. None of the patients presented with a known family history of HLRCC or was specifically suspected for this syndrome by clinicians at the initial presentation. All patients underwent radical or partial nephrectomy and were found to have at least a pT3 tumor and regional lymph node involvement. Seven of the 9 patients developed distant metastases involving lung, liver, bone, and other sites, and 5 patients died of the disease during a mean follow-up period of 15 months (median 10 mo).
On the basis of histologic features, the possibility of HLRCC was raised by pathologic examination at the time of diagnosis in 7 cases, which led to subsequent genetic counseling and identification of FH germline mutations. Compared with routine clinical encounters, genetic counseling in these patients revealed more evidence suggesting an association with the HLRCC syndrome. In 6 of these patients additional histories of prior cutaneous lesions, uterine fibroids, and RCC in second-degree or third-degree relatives were elicited in 3, 1, and 2 cases, respectively.
HLRCC Renal Tumors Exhibit an Expanding Morphologic Spectrum
Histologically, these tumors displayed a spectrum of architectural patterns. As previously described by Merino (Figs. 1E, F) . Mixed architectural patterns were noted in all 9 tumors (Table 2) . Papillary was seen as the dominant pattern in only 3 tumors. The dominant patterns in other tumors were tubulopapillary (n = 5) and solid (n = 1). The papillary, tubulopapillary, tubular, and cystic areas were often intermixed. Notably, the fibrovascular cores in papillae were often hyalinized (Fig. 1F) or showed edematous changes, while only rarely containing foamy histiocytes. Micropapillary fronds were also frequently seen in papillary elements (Fig. 1A) . CDC-like areas were found to be common in this cohort, with tubules, solid nests, or individual cells infiltrating a desmoplastic stroma (Figs. 2A, B) . Intratumoral inflammatory infiltrates were also prominent in 3 of these 6 tumors. In addition, some tumors contained a tubulocystic component that closely resembled tubulocystic carcinoma, with variably sized tubules, some cystically dilated, in a hypocellular and fibrotic stroma (Figs. 2C, D) . The lining cells in the tubulocystic component showed prominent nucleoli and focally a hobnail appearance. Although this tubulocystic pattern was prominent and presented as distinct areas or tumor nodules, other growth patterns such as tubulopapillary, solid, or infiltrating tubules were identified in the remaining portions of all 3 tumors. In addition, sarcomatoid growth was identified in 1 tumor, consisting of sheets of spindle cells (Fig. 2E) . Moreover, 3 cases showed prominent intracytoplasmic and/or intercellular vacuoles, imparting a sieve-like or cribriform appearance (Fig. 2F) . This sievelike/cribriform pattern was seen in areas of all growth patterns, including tubular, papillary, solid, and cystic.
The cytoplasm of the tumor cells was predominantly eosinophilic; however, focal areas containing more amphophilic or clear cytoplasm were also noted. Although all tumors exhibited the proposed hallmark of HLRCC, a large viral inclusion-like eosinophilic nucleolus surrounded by a clear halo, this feature was often not uniformly present throughout the tumor (Figs. 1, 2) . Within areas of a given tumor, the characteristic nuclear finding could be apparent only in scattered cells, whereas other tumor cells displayed smaller nucleoli without a distinct perinucleolar halo, thus requiring careful microscopic evaluation in tumors with such focal changes.
2SC Immunoreactivity in HLRCC and Other High-grade RCCs With Prominent Nucleoli
Given this broad architectural and cytologic spectrum noted in HLRCC tumors, the differential diagnosis could include a variety of high-grade RCCs exhibiting prominent nucleoli. Although the inclusion-like nucleoli and perinucleolar halo of HLRCC renal tumors were quite unique, in our experience, occasionally a non-HLRCC high-grade RCC can also focally show macronucleoli with perinucleolar clearing, mimicking the characteristics of HLRCC. To test the utility of 2SC immunohistochemistry in helping distinguish HLRCC renal tumors from other high-grade RCCs, 2SC immunoreactivity was performed in HLRCC renal tumors and the results compared with 184 clear cell RCCs, 45 papillary RCCs with type 2 features, and 97 high-grade unclassified RCC cases, as well as Xp11 translocation RCC and renal medullary carcinoma that showed nuclear features raising concern for HLRCC.
All confirmed HLRCC tumors (9/9, 100%) demonstrated diffuse and strong staining for 2SC, whereas the adjacent renal parenchyma was negative (Fig. 3) . In contrast, all clear cell RCC cases (184/184, 100%), almost all high-grade unclassified RCCs (93/97, 96%), and the large majority of type 2 papillary (35/45, 78%) cases showed no 2SC immunoreactivity. Two Xp11 translocation-associated tumors and 2 renal medullary carcinomas were also negative. This lack of 2SC immunoreactivity was observed for the majority of tumors in these groups that displayed nuclear features imitating HLRCC tumors (Fig. 4) .
Only a subset of type 2 papillary (10/45, 22%) and high-grade unclassified (4/97, 5%) tumors showed patchy or diffuse 2SC immunostaining. Interestingly, unlike the nuclear and cytoplasmic staining pattern seen in all 9 confirmed HLRCC tumors, the 2SC staining pattern in these cases was predominantly cytoplasmic (Fig. 5) .
Correlation Between 2SC Immunoreactivity and FH Molecular Aberrations
To further evaluate the correlation between 2SC immunohistochemistry and a diagnosis of HLRCC renal tumors or the presence of other potential molecular aberrations of the FH gene, we conducted molecular analysis of the FH gene by targeted deep sequencing in 16 cases demonstrating HLRCC or HLRCC-like nuclear features and showing various 2SC staining patterns. In addition, FH genetic testing results were available in another 7 cases. These results are summarized in Table 3 . For confirmed HLRCC cases, besides the germline FH mutations, a "second-hit," either a second somatic mutation of FH gene or loss of heterozygosity, was identified in 3 cases for which we also analyzed somatic alterations in tumor tissue. All other 14 cases sequenced, despite displaying nuclear features mimicking HLRCC, had no germline or somatic alterations of FH gene, nor did they show the same 2SC staining pattern as in confirmed HLRCC tumors. These included the 3 unclassified RCC and 2 type 2 papillary RCC cases that exhibited diffuse or patchy cytoplasmic 2SC immunoreactivity, as well as another 9 cases that were negative for 2SC staining.
DISCUSSION
First described by Launonen et al 1 in 2001, the HLRCC syndrome is now known to confer an increased risk for RCCs and smooth muscle tumors of the skin and uterus. 21 Within the spectrum of this syndromic disease, renal carcinoma is the most aggressive presentation and cause of mortality. Therefore, pathologic suspicion or diagnosis of HLRCC-associated RCC is critical for appropriate clinical management and genetic counseling of the family members. Recently, HLRCC renal cancer has been recommended to be recognized as a distinct entity in the International Society of Urological Pathology Vancouver Classification of Renal Neoplasia. 22 However, these are often solitary tumors exhibiting a broad morphologic spectrum, posing a difficult diagnostic challenge.
In our experience, it is not uncommon for a renal mass to be the first recognized manifestation that brings clinical attention to a patient's genetic syndrome, possibly because of the asymptomatic nature of many of the cutaneous leiomyomas and the relative frequency of uterine leiomyomas in the general population. Families presenting with RCC only have also been reported in the literature. 6 In this study, we summarize our experience in diagnosing HLRCC renal tumors that presented as sporadic RCCs and describe their expanding clinicopathologic features. All of the confirmed HLRCC renal tumor cases in our cohort had no known family history of HLRCC at their initial presentations. Consistent with the incomplete penetrance of renal cancers in this syndrome, only 2 of the 9 patients had a family history of RCC in first-degree relatives. Other types of cancer (eg, lung, breast, etc.) that have not been associated with HLRCC syndrome were seen in some family members. Although skin or uterine leiomyomas tend to have high penetrance compared with renal tumors, it was often difficult to elicit this history or evidence of these lesions in routine clinical encounters, particularly when there are no obvious symptoms. This finding is in line with the previous reports that about 40% HLRCC families only had either mild cutaneous presentations (< 5 leiomyomas) or lacked skin lesions. 3, 5 In cases in which there was little or no clinical evidence suggesting HLRCC, a suspicion raised by pathologists based on histologic features was often the key step leading to additional clinical workup and genetic counseling that established the diagnosis.
Compared with sporadic RCC in general, patients with HLRCC renal tumors presented at a younger age (mean 36 y). However, this disease is not limited to young patients: the oldest patient in our cohort was 61 years old; in a previous study, 7 9 of 38 (24%) patients were older than 50. These renal tumors frequently presented at an advanced pathologic stage, with involvement of regional lymph nodes being a common finding at nephrectomy. Some authors have suggested that the morphology of these tumors is that of type 2 papillary RCC. In this cohort, we found that RCC associated with this syndrome frequently displayed mixed architectural patterns, similar to that described by Merino et al. 7 In fact, patterns other than papillary were frequently the dominant component. Besides papillary, tubulopapillary, tubular, solid, and cystic elements, CDC-like areas with infiltrating tubules, nests, or individual cells in a desmoplastic stroma were identified in more than half of the cases, emphasizing the morphologic similarities between HLRCC renal tumors and CDCs.
Similarly, 3 cases contained tubulocystic areas closely resembling tubulocystic carcinoma, yet all containing other components (tubulopapillary and papillary patterns). This coexistence of tubulocystic carcinoma-like elements with other architectural patterns in HLRCC renal tumors suggests it being considered as an important differential diagnosis for cases described in the literature as tubulocystic carcinoma with mixed papillary, solid, or dedifferentiated components. [23] [24] [25] [26] It remains unknown whether HLRCC renal tumors could consist exclusively or almost exclusively of a tubulocystic element, although most of the tubulocystic carcinomas described are pure, well-circumscribed tumors with overall good prognosis. 27 In an array comparative genomic hybridization study of renal tumors associated with HLRCC, 28 about 30% to 40% HLRCC tumors appeared to harbor chromosomal 7 or 17 gains, suggesting that trisomy 7 or 17 by FISH is not a reliable marker to separate HLRCC renal cancer from sporadic papillary RCC or tubulocystic carcinoma.
In addition, we observed a cribriform pattern (some due to abundant intracytoplasmic or intercellular vacuoles), clear cell features, and sarcomatoid differentiation within the morphologic spectrum of genetically confirmed HLRCC tumors. These features and the mixed architectural patterns raise multiple differential diagnostic possibilities, including renal medullary carcinoma, Xp11 or t (6,11) translocation RCC, high-grade clear cell RCC and high-grade unclassified RCC.
Although the most distinctive morphologic feature of HLRCC tumors, a prominent eosinophilic nucleolus with a clear perinucleolar halo, was indeed present in all genetically confirmed cases, its presence was nonuniform. Confounding the diagnostic difficulty, almost all other high-grade RCCs in the differential diagnosis of HLRCC had prominent nucleoli, occasionally showing HLRCClike nuclear features (Fig. 4) , although usually limited to focal areas or in scattered cells. With the exception of a few specific ancillary studies, such as INI1 (SMARCB1) loss by immunohistochemistry and TFE3/TFEB immunostaining or FISH tests, immunohistochemical panels used for the classification of renal neoplasms are generally not very helpful for distinguishing HLRCC tumors from these other high-grade RCC cases.
We investigated the utility of 2SC immunohistochemistry, a marker to detect the aberrant succination of proteins in cells with high levels of fumarate, in this challenging diagnostic scenario and correlated the 2SC immunoreactivity to the presence of FH germline mutation. Among the various subtypes of RCC tested by us, 2SC immunostaining appeared to be a very sensitive marker for HLRCC tumors. All confirmed cases showed diffuse and strong nuclear and cytoplasmic staining; conversely, none of the tumors with negative 2SC staining in the molecularly characterized subset was found to harbor FH germline alterations. This high sensitivity is in keeping with the finding reported by Bardella et al. 11 In addition, we identified a small subset of unclassified and type 2 papillary RCCs that exhibited immunoreactivity to 2SC but did not harbor FH germline or somatic alterations. However, the 2SC immunoreactivity observed in this subset was only cytoplasmic staining, unlike that found in HLRCC tumors (nuclear and cytoplasmic). Although further validation is required, if one uses the latter pattern (nuclear and cytoplasmic labeling) as the criterion for judging 2SC in the setting of diagnosing HLRCC tumors, then 2SC immunohistochemistry supports a diagnosis of HLRCC in a highly specific manner.
In contrast to typical immunohistochemistry assays in which a peptide/protein is the specific antigen, 2SC immunohistochemistry stains all the proteins with the stable 2SC modification (succination). Therefore, in different cellular contexts, the staining pattern could vary. A recent study utilized a proteomic-based screen and identified 94 protein succination targets in cells and renal cysts of Fh1 (murine FH)-deficient mice. 29 These targets included a broad range of nuclear, cytoplasmic, and mitochondrial proteins, suggesting that nuclear protein succination could be a feature of HLRCC tumors. Whether the non-nuclear 2SC staining pattern we identified in the small number of non-HLRCC cases represents a different mechanism of fumarate accumulation or is due to other unknown causes requires future investigation.
In addition, although we found the 2SC immunohistochemistry to be a very helpful aid in diagnosing HLRCC tumors, the antibody is not yet commercially available, and the assay is only being performed in a limited number of laboratories.
The molecular characterization conducted by us revealed somatic inactivation of the remaining FH allele in HLRCC renal cancer, which is consistent with the role of FH as a tumor-suppressor gene. Its loss of function in the tumor cells corresponded to strong 2SC staining, whereas adjacent renal parenchyma maintained a wild-type allele and did not show 2SC immunoreactivity. On the basis of a limited sample in this cohort, somatic mutation of FH seems to be a rare event in non-HLRCC renal tumors that showed nuclear features imitating HLRCC.
In summary, our results suggest that a combination of careful histologic examination and 2SC immunohistochemistry can greatly increase our ability to recognize HLRCC-associated RCC, a group of tumors with an expanding histologic spectrum that mimic many other highgrade renal tumors. As a useful ancillary tool, 2SC immunohistochemistry helps us improve the specificity when we raise a suspicion for this aggressive hereditary condition 
